Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Deutsche Bank AG — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Deutsche Bank AG trades at $35.11 (market cap $70.38B). The key difference: Deutsche Bank AG is far larger — about 15.7× ACADIA Pharmaceuticals Inc.'s market cap, and Deutsche Bank AG pays a 3.17% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DB | |
|---|---|---|
Market Cap | $4.49B | $70.38B |
Sector | Health | Financials |
52-Week High | $28.06 | $40.33 |
52-Week Low | $20.06 | $28.37 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Deutsche Bank (DB) trades at $36.64, up 2.18% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamental momentum with three consecutive quarterly EPS beats and a net income margin of 21.98% for 2025. Recent strategic moves include selling its India retail unit to Kotak to sharpen focus on higher-growth businesses, while maintaining a dividend payout of $1.00 for H1-26.
The outlook remains positive with revenue growth to $32.2B projected for 2026 and a profit margin of 21.97%. Investment opportunities include attractive valuation with P/E of 10.29 and P/B of 0.8, but risks involve negative operating cash flow of -$28.58B in 2024 and competitive pressures from JPMorgan's expansion in Germany.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
